Circulation. 2005;111:3261-3268
Published online before print June 13, 2005,
doi: 10.1161/CIRCULATIONAHA.105.534024
(Circulation. 2005;111:3261-3268.)
© 2005 American Heart Association, Inc.
Rho-Kinase Mediates Hyperglycemia-Induced Plasminogen Activator Inhibitor-1 Expression in Vascular Endothelial Cells
Yoshiyuki Rikitake, MD, PhD;
James K. Liao, MD
From the Vascular Medicine Research Unit, Brigham and Womens Hospital and Harvard Medical School, Boston, Mass.
Correspondence to James K. Liao, MD, Brigham and Womens Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139. E-mail jliao{at}rics.bwh.harvard.edu
Received January 4, 2005; revision received February 22, 2005; accepted March 2, 2005.
Background Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes. The induction of PAI-1 expression by hyperglycemia involves oxidative stress and protein kinase C (PKC). However, the mechanism by which hyperglycemia increases PAI-1 expression is unknown.
Methods and Results Compared with normoglycemia, exposure of human endothelial cells to hyperglycemia, but not mannitol, increased Rho-kinase activity in a time- and concentration-dependent manner. This increase was inhibited by a PKC inhibitor, GF109203X, and antioxidants N-acetylcysteine (NAC) and reduced form of glutathione (GSH). This correlated with inhibition of hyperglycemia-induced PAI-1 expression by GF109203X, NAC, and GSH. Hyperglycemia-increased PAI-1 mRNA and protein levels were inhibited by Rho-kinase inhibitors hydroxyfasudil and Y27632 and by a dominant-negative mutant of Rho-kinase. The mechanism for this inhibition occurs at the level of gene transcription because Rho-kinase inhibitors repress hyperglycemia-stimulated PAI-1 promoter activity without affecting mRNA stability. Hyperglycemia failed to stimulate Rho-kinase activity and PAI-1 expression in heterozygous ROCK Iknockout murine endothelial cells.
Conclusions Hyperglycemia stimulates Rho-kinase activity via PKC- and oxidative stressdependent pathways, leading to increased PAI-1 gene transcription. These results suggest that inhibition of ROCK I may be a novel therapeutic target for preventing thromboembolic complications of diabetes and cardiovascular disease.
Key Words: diabetes mellitus glucose molecular biology plasminogen
This article has been cited by other articles:

|
 |

|
 |
 
V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh
Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control
Diabetes,
March 1, 2008;
57(3):
714 - 723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Jensen, B. Sloth, I. Krog-Mikkelsen, A. Flint, A. Raben, T. Tholstrup, N. Brunner, and A. Astrup
A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women
Am. J. Clinical Nutrition,
January 1, 2008;
87(1):
97 - 105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Goel, Y. Zhang, L. Anderson, and R. Rahimian
Gender difference in rat aorta vasodilation after acute exposure to high glucose: Involvement of protein kinase C {beta} and superoxide but not of Rho Kinase
Cardiovasc Res,
November 1, 2007;
76(2):
351 - 360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Henke, R. Schmidt-Ullrich, R. Dechend, J.-K. Park, F. Qadri, M. Wellner, M. Obst, V. Gross, R. Dietz, F. C. Luft, et al.
Vascular Endothelial Cell Specific NF-{kappa}B Suppression Attenuates Hypertension-Induced Renal Damage
Circ. Res.,
August 3, 2007;
101(3):
268 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao
Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome
J. Am. Coll. Cardiol.,
April 17, 2007;
49(15):
1619 - 1624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nohria, M. E. Grunert, Y. Rikitake, K. Noma, A. Prsic, P. Ganz, J. K. Liao, and M. A. Creager
Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease
Circ. Res.,
December 8, 2006;
99(12):
1426 - 1432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chrissobolis and C. G. Sobey
Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease
Stroke,
August 1, 2006;
37(8):
2174 - 2180.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Yang, T. A. Doser, C. X. Fang, J. M. Nunn, R. Janardhanan, M. Zhu, N. Sreejayan, M. T. Quinn, and J. Ren
Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress
FASEB J,
May 1, 2006;
20(7):
1024 - 1026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Noma, N. Oyama, and J. K. Liao
Physiological role of ROCKs in the cardiovascular system
Am J Physiol Cell Physiol,
March 1, 2006;
290(3):
C661 - C668.
[Abstract]
[Full Text]
[PDF]
|
 |
|